BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Alcohol
,
Lipitor
,
rs4950928
,
PDX1
,
glucose metabolic process
,
Pseudomonas infection
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
hdacs protein
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Umbilical vein endothelial HUVEC cells treated with small molecule perturbagens
L1000 CMAP - Bone marrow CD34 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Targeting class I histone deacetylases in cancer therapy.
Energy based pharmacophore mapping of HDAC inhibitors against class I HDAC enzymes.
Histone deacetylases and their functions in plants.
The potential of HDAC inhibitors as cognitive enhancers.
Histone deacetylases and their role in asthma.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Rel…
Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patien…
phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ